JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB312598

重组Alexa Fluor® 568荧光Anti-RUNX1 / AML1 + RUNX3 + RUNX2抗体[EPR3099]

Alexa Fluor® 568 Anti-RUNX1 / AML1 + RUNX3 + RUNX2 antibody [EPR3099]

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Recombinant Monoclonal RUNX1 / AML1 antibody - conjugated to Alexa Fluor® 568.

查看别名

AML1, CBFA2, RUNX1, Runt-related transcription factor 1, Acute myeloid leukemia 1 protein, Core-binding factor subunit alpha-2, Oncogene AML-1, Polyomavirus enhancer-binding protein 2 alpha B subunit, SL3-3 enhancer factor 1 alpha B subunit, SL3/AKV core-binding factor alpha B subunit, CBF-alpha-2, PEA2-alpha B, PEBP2-alpha B

不同偶联物与剂型 (8)

  • 665 Alexa Fluor® 647

    Alexa Fluor® 647 Anti-RUNX1 / AML1 + RUNX3 + RUNX2 antibody [EPR3099]

  • 519 Alexa Fluor® 488

    Alexa Fluor® 488 Anti-RUNX1 / AML1 + RUNX3 + RUNX2 antibody [EPR3099]

  • 617 Alexa Fluor® 594

    Alexa Fluor® 594 Anti-RUNX1 / AML1+RUNX3+RUNX2 antibody [EPR3099]

  • 565 Alexa Fluor® 555

    Alexa Fluor® 555 Anti-RUNX1 / AML1+RUNX3+RUNX2 antibody [EPR3099]

  • 578 PE

    PE Anti-RUNX1 / AML1 + RUNX3 + RUNX2 antibody [EPR3099]

  • 660 APC

    APC Anti-RUNX1 / AML1 + RUNX3 + RUNX2 antibody [EPR3099]

  • HRP

    HRP Anti-RUNX1 / AML1 + RUNX3 + RUNX2 antibody [EPR3099]

  • 775 Alexa Fluor® 750

    Alexa Fluor® 750 Anti-RUNX1 / AML1 + RUNX3 + RUNX2 antibody [EPR3099]

关键信息

宿主种属

Rabbit

克隆

Monoclonal

克隆号

EPR3099

亚型

IgG

偶联物

Alexa Fluor® 568

激发波长/发射波长

Ex: 578nm, Em: 603nm

不含载体蛋白

No

应用

Antibody Labelling, Target Binding Affinity

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

产品详情

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

性能和储存信息

形式
Liquid
纯化工艺
Affinity purification Protein A
存储溶液
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
运输条件
Blue Ice
推荐的短期储存时间
1-2 weeks
推荐的短期储存条件
+4°C
推荐的长期储存条件
-20°C
分装信息
Upon delivery aliquot
储存信息
Avoid freeze / thaw cycle|Store in the dark

补充信息

This supplementary information is collated from multiple sources and compiled automatically.

RUNX1 also known as AML1 along with RUNX2 and RUNX3 form a family of transcription factors that play a critical role in gene regulation. These proteins recognize specific DNA sequences through their Runt domain facilitating DNA binding and transcriptional activation or repression. RUNX1 is extensively studied having a mass of approximately 48 kDa. They are expressed in various tissues including hematopoietic cells osteoblasts and the central nervous system. RUNX proteins regulate genes involved in cell differentiation and proliferation.
Biological function summary

RUNX1 RUNX2 and RUNX3 control processes in development and differentiation. They often function as part of a transcriptional complex with CBFβ enhancing DNA binding and transcriptional activity. RUNX1 is vital in hematopoiesis guiding the formation of blood cells. RUNX2 predominantly influences bone development by regulating osteoblast differentiation while RUNX3 impacts neural development and T-cell maturation. These proteins collectively integrate signals to ensure proper cell lineage decisions.

Pathways

RUNX proteins participate in essential cellular pathways like the Wnt and TGF-β signaling pathways. The Wnt pathway involves interaction with β-catenin affecting cell fate and development processes. RUNX2 plays a significant role here by contributing to bone formation. The TGF-β pathway influences cell growth and differentiation by interacting with SMAD proteins primarily through RUNX3 which modulates immune responses and tumorigenesis. These pathways highlight RUNX proteins' critical integration in signaling networks.

RUNX1 mutations associate with various hematological malignancies notably acute myeloid leukemia (AML). RUNX1 mutations disrupt normal hematopoiesis leading to uncontrolled cell proliferation. RUNX2's dysregulation relates to cleidocranial dysplasia a skeletal disorder characterized by delayed bone development. Both RUNX1 and RUNX2 link to similar signaling pathways such as the Wnt pathway implicating them in these diseases' pathogenesis. Understanding RUNX proteins' role can lead to better diagnostic and therapeutic approaches for these conditions.

产品实验方案

For this product, it's our understanding that no specific protocols are required. You can visit:

靶点信息

Forms the heterodimeric complex core-binding factor (CBF) with CBFB. RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. The heterodimers bind to the core site of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL3 and GM-CSF promoters (Probable). Essential for the development of normal hematopoiesis (PubMed : 17431401). Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the BLK promoter (PubMed : 10207087, PubMed : 14970218). Inhibits KAT6B-dependent transcriptional activation (By similarity). Involved in lineage commitment of immature T cell precursors. CBF complexes repress ZBTB7B transcription factor during cytotoxic (CD8+) T cell development. They bind to RUNX-binding sequence within the ZBTB7B locus acting as transcriptional silencer and allowing for cytotoxic T cell differentiation. CBF complexes binding to the transcriptional silencer is essential for recruitment of nuclear protein complexes that catalyze epigenetic modifications to establish epigenetic ZBTB7B silencing (By similarity). Controls the anergy and suppressive function of regulatory T-cells (Treg) by associating with FOXP3. Activates the expression of IL2 and IFNG and down-regulates the expression of TNFRSF18, IL2RA and CTLA4, in conventional T-cells (PubMed : 17377532). Positively regulates the expression of RORC in T-helper 17 cells (By similarity).. Isoform AML-1G shows higher binding activities for target genes and binds TCR-beta-E2 and RAG-1 target site with threefold higher affinity than other isoforms. It is less effective in the context of neutrophil terminal differentiation.. Isoform AML-1L interferes with the transactivation activity of RUNX1.
See full target information RUNX1

Abcam Product Promise

我们致力于为您的研究提供高质量的试剂,为您科研的每一步提供支持。若我们的产品未能达到预期性能,我们向您提供 Abcam Product Promise 保障。
详情请参阅我们的条款与条件。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com